- call +1-201-465-4211
- email sales@marketquest.biz
- Call +1-201-465-4211
- Email: sales@marketquest.biz
Recombinant human coagulation factor VIIa is a drug from Novo Nordisk for bleeding episodes and prevention of bleeding during surgical procedures or invasive procedures in the following patient groups:
1. Inhibitors of coagulation factor VIII or IX 5BU in congenital hemophilia patients; 2. Congenital hemophilia patients who are expected to have a high memory response to injection of coagulation factor VIII or coagulation factor IX; 3. Acquired blood 4. Patients with congenital FVII deficiency; 5. Patients with thrombocytopenia who have GP IIb-IIIa and/or HLA antibodies and past or present ineffective or poor platelet transfusions.
According to our latest study, the global Eptacog Alfa (rFVIIa) market size was valued at USD 1224.5 million in 2022 and is forecast to a readjusted size of USD 1655.4 million by 2029 with a CAGR of 4.4% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Novo Nordisk is the largest manufacturers of eptacog alfa (rFVIIa) in the world, has a share about 92%. Other players include LFB SA, GENERIUM,Northland-bio, and Northland-bioi, etc. The key players are mainly located in Europe, North America, China, and Japan. In terms of product, freeze-dried preparation is the largest segment, with a share over 52%. And in terms of application, the largest application is hemophilia, with a share over 48%, followed by acquired hemophilia.
This report is a detailed and comprehensive analysis for global Eptacog Alfa (rFVIIa) market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Eptacog Alfa (rFVIIa) market size and forecasts, in consumption value ($ Million), sales quantity (g), and average selling prices (US$/mg), 2018-2029
Global Eptacog Alfa (rFVIIa) market size and forecasts by region and country, in consumption value ($ Million), sales quantity (g), and average selling prices (US$/mg), 2018-2029
Global Eptacog Alfa (rFVIIa) market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (g), and average selling prices (US$/mg), 2018-2029
Global Eptacog Alfa (rFVIIa) market shares of main players, shipments in revenue ($ Million), sales quantity (g), and ASP (US$/mg), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Eptacog Alfa (rFVIIa)
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Eptacog Alfa (rFVIIa) market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novo Nordisk, LFB SA, GENERIUM, Northland-bio and CSL, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Eptacog Alfa (rFVIIa) market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Freeze-dried Preparation
Freeze-dried Powder
Market segment by Application
Hemophilia
Acquired Hemophilia
Factor VII Deficiency
Glanzmann Thrombasthenia (GT)
Major players covered
Novo Nordisk
LFB SA
GENERIUM
Northland-bio
CSL
Shire (Takeda)
Bayer
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Eptacog Alfa (rFVIIa) product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Eptacog Alfa (rFVIIa), with price, sales, revenue and global market share of Eptacog Alfa (rFVIIa) from 2018 to 2023.
Chapter 3, the Eptacog Alfa (rFVIIa) competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Eptacog Alfa (rFVIIa) breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Eptacog Alfa (rFVIIa) market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Eptacog Alfa (rFVIIa).
Chapter 14 and 15, to describe Eptacog Alfa (rFVIIa) sales channel, distributors, customers, research findings and conclusion.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Product Overview and Scope of Eptacog Alfa (rFVIIa)
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Eptacog Alfa (rFVIIa) Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Freeze-dried Preparation
1.3.3 Freeze-dried Powder
1.4 Market Analysis by Application
1.4.1 Overview: Global Eptacog Alfa (rFVIIa) Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hemophilia
1.4.3 Acquired Hemophilia
1.4.4 Factor VII Deficiency
1.4.5 Glanzmann Thrombasthenia (GT)
1.5 Global Eptacog Alfa (rFVIIa) Market Size & Forecast
1.5.1 Global Eptacog Alfa (rFVIIa) Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Eptacog Alfa (rFVIIa) Sales Quantity (2018-2029)
1.5.3 Global Eptacog Alfa (rFVIIa) Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Novo Nordisk
2.1.1 Novo Nordisk Details
2.1.2 Novo Nordisk Major Business
2.1.3 Novo Nordisk Eptacog Alfa (rFVIIa) Product and Services
2.1.4 Novo Nordisk Eptacog Alfa (rFVIIa) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Novo Nordisk Recent Developments/Updates
2.2 LFB SA
2.2.1 LFB SA Details
2.2.2 LFB SA Major Business
2.2.3 LFB SA Eptacog Alfa (rFVIIa) Product and Services
2.2.4 LFB SA Eptacog Alfa (rFVIIa) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 LFB SA Recent Developments/Updates
2.3 GENERIUM
2.3.1 GENERIUM Details
2.3.2 GENERIUM Major Business
2.3.3 GENERIUM Eptacog Alfa (rFVIIa) Product and Services
2.3.4 GENERIUM Eptacog Alfa (rFVIIa) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 GENERIUM Recent Developments/Updates
2.4 Northland-bio
2.4.1 Northland-bio Details
2.4.2 Northland-bio Major Business
2.4.3 Northland-bio Eptacog Alfa (rFVIIa) Product and Services
2.4.4 Northland-bio Eptacog Alfa (rFVIIa) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Northland-bio Recent Developments/Updates
2.5 CSL
2.5.1 CSL Details
2.5.2 CSL Major Business
2.5.3 CSL Eptacog Alfa (rFVIIa) Product and Services
2.5.4 CSL Eptacog Alfa (rFVIIa) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 CSL Recent Developments/Updates
2.6 Shire (Takeda)
2.6.1 Shire (Takeda) Details
2.6.2 Shire (Takeda) Major Business
2.6.3 Shire (Takeda) Eptacog Alfa (rFVIIa) Product and Services
2.6.4 Shire (Takeda) Eptacog Alfa (rFVIIa) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Shire (Takeda) Recent Developments/Updates
2.7 Bayer
2.7.1 Bayer Details
2.7.2 Bayer Major Business
2.7.3 Bayer Eptacog Alfa (rFVIIa) Product and Services
2.7.4 Bayer Eptacog Alfa (rFVIIa) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Bayer Recent Developments/Updates
3 Competitive Environment: Eptacog Alfa (rFVIIa) by Manufacturer
3.1 Global Eptacog Alfa (rFVIIa) Sales Quantity by Manufacturer (2018-2023)
3.2 Global Eptacog Alfa (rFVIIa) Revenue by Manufacturer (2018-2023)
3.3 Global Eptacog Alfa (rFVIIa) Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Eptacog Alfa (rFVIIa) by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Eptacog Alfa (rFVIIa) Manufacturer Market Share in 2022
3.4.2 Top 6 Eptacog Alfa (rFVIIa) Manufacturer Market Share in 2022
3.5 Eptacog Alfa (rFVIIa) Market: Overall Company Footprint Analysis
3.5.1 Eptacog Alfa (rFVIIa) Market: Region Footprint
3.5.2 Eptacog Alfa (rFVIIa) Market: Company Product Type Footprint
3.5.3 Eptacog Alfa (rFVIIa) Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Eptacog Alfa (rFVIIa) Market Size by Region
4.1.1 Global Eptacog Alfa (rFVIIa) Sales Quantity by Region (2018-2029)
4.1.2 Global Eptacog Alfa (rFVIIa) Consumption Value by Region (2018-2029)
4.1.3 Global Eptacog Alfa (rFVIIa) Average Price by Region (2018-2029)
4.2 North America Eptacog Alfa (rFVIIa) Consumption Value (2018-2029)
4.3 Europe Eptacog Alfa (rFVIIa) Consumption Value (2018-2029)
4.4 Asia-Pacific Eptacog Alfa (rFVIIa) Consumption Value (2018-2029)
4.5 South America Eptacog Alfa (rFVIIa) Consumption Value (2018-2029)
4.6 Middle East and Africa Eptacog Alfa (rFVIIa) Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Eptacog Alfa (rFVIIa) Sales Quantity by Type (2018-2029)
5.2 Global Eptacog Alfa (rFVIIa) Consumption Value by Type (2018-2029)
5.3 Global Eptacog Alfa (rFVIIa) Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Eptacog Alfa (rFVIIa) Sales Quantity by Application (2018-2029)
6.2 Global Eptacog Alfa (rFVIIa) Consumption Value by Application (2018-2029)
6.3 Global Eptacog Alfa (rFVIIa) Average Price by Application (2018-2029)
7 North America
7.1 North America Eptacog Alfa (rFVIIa) Sales Quantity by Type (2018-2029)
7.2 North America Eptacog Alfa (rFVIIa) Sales Quantity by Application (2018-2029)
7.3 North America Eptacog Alfa (rFVIIa) Market Size by Country
7.3.1 North America Eptacog Alfa (rFVIIa) Sales Quantity by Country (2018-2029)
7.3.2 North America Eptacog Alfa (rFVIIa) Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Eptacog Alfa (rFVIIa) Sales Quantity by Type (2018-2029)
8.2 Europe Eptacog Alfa (rFVIIa) Sales Quantity by Application (2018-2029)
8.3 Europe Eptacog Alfa (rFVIIa) Market Size by Country
8.3.1 Europe Eptacog Alfa (rFVIIa) Sales Quantity by Country (2018-2029)
8.3.2 Europe Eptacog Alfa (rFVIIa) Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Eptacog Alfa (rFVIIa) Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Eptacog Alfa (rFVIIa) Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Eptacog Alfa (rFVIIa) Market Size by Region
9.3.1 Asia-Pacific Eptacog Alfa (rFVIIa) Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Eptacog Alfa (rFVIIa) Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Eptacog Alfa (rFVIIa) Sales Quantity by Type (2018-2029)
10.2 South America Eptacog Alfa (rFVIIa) Sales Quantity by Application (2018-2029)
10.3 South America Eptacog Alfa (rFVIIa) Market Size by Country
10.3.1 South America Eptacog Alfa (rFVIIa) Sales Quantity by Country (2018-2029)
10.3.2 South America Eptacog Alfa (rFVIIa) Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Eptacog Alfa (rFVIIa) Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Eptacog Alfa (rFVIIa) Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Eptacog Alfa (rFVIIa) Market Size by Country
11.3.1 Middle East & Africa Eptacog Alfa (rFVIIa) Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Eptacog Alfa (rFVIIa) Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Eptacog Alfa (rFVIIa) Market Drivers
12.2 Eptacog Alfa (rFVIIa) Market Restraints
12.3 Eptacog Alfa (rFVIIa) Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Eptacog Alfa (rFVIIa) and Key Manufacturers
13.2 Manufacturing Costs Percentage of Eptacog Alfa (rFVIIa)
13.3 Eptacog Alfa (rFVIIa) Production Process
13.4 Eptacog Alfa (rFVIIa) Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Eptacog Alfa (rFVIIa) Typical Distributors
14.3 Eptacog Alfa (rFVIIa) Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
List of Tables
Table 1. Global Eptacog Alfa (rFVIIa) Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Eptacog Alfa (rFVIIa) Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Novo Nordisk Basic Information, Manufacturing Base and Competitors
Table 4. Novo Nordisk Major Business
Table 5. Novo Nordisk Eptacog Alfa (rFVIIa) Product and Services
Table 6. Novo Nordisk Eptacog Alfa (rFVIIa) Sales Quantity (g), Average Price (US$/mg), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Novo Nordisk Recent Developments/Updates
Table 8. LFB SA Basic Information, Manufacturing Base and Competitors
Table 9. LFB SA Major Business
Table 10. LFB SA Eptacog Alfa (rFVIIa) Product and Services
Table 11. LFB SA Eptacog Alfa (rFVIIa) Sales Quantity (g), Average Price (US$/mg), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. LFB SA Recent Developments/Updates
Table 13. GENERIUM Basic Information, Manufacturing Base and Competitors
Table 14. GENERIUM Major Business
Table 15. GENERIUM Eptacog Alfa (rFVIIa) Product and Services
Table 16. GENERIUM Eptacog Alfa (rFVIIa) Sales Quantity (g), Average Price (US$/mg), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. GENERIUM Recent Developments/Updates
Table 18. Northland-bio Basic Information, Manufacturing Base and Competitors
Table 19. Northland-bio Major Business
Table 20. Northland-bio Eptacog Alfa (rFVIIa) Product and Services
Table 21. Northland-bio Eptacog Alfa (rFVIIa) Sales Quantity (g), Average Price (US$/mg), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Northland-bio Recent Developments/Updates
Table 23. CSL Basic Information, Manufacturing Base and Competitors
Table 24. CSL Major Business
Table 25. CSL Eptacog Alfa (rFVIIa) Product and Services
Table 26. CSL Eptacog Alfa (rFVIIa) Sales Quantity (g), Average Price (US$/mg), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. CSL Recent Developments/Updates
Table 28. Shire (Takeda) Basic Information, Manufacturing Base and Competitors
Table 29. Shire (Takeda) Major Business
Table 30. Shire (Takeda) Eptacog Alfa (rFVIIa) Product and Services
Table 31. Shire (Takeda) Eptacog Alfa (rFVIIa) Sales Quantity (g), Average Price (US$/mg), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Shire (Takeda) Recent Developments/Updates
Table 33. Bayer Basic Information, Manufacturing Base and Competitors
Table 34. Bayer Major Business
Table 35. Bayer Eptacog Alfa (rFVIIa) Product and Services
Table 36. Bayer Eptacog Alfa (rFVIIa) Sales Quantity (g), Average Price (US$/mg), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Bayer Recent Developments/Updates
Table 38. Global Eptacog Alfa (rFVIIa) Sales Quantity by Manufacturer (2018-2023) & (g)
Table 39. Global Eptacog Alfa (rFVIIa) Revenue by Manufacturer (2018-2023) & (USD Million)
Table 40. Global Eptacog Alfa (rFVIIa) Average Price by Manufacturer (2018-2023) & (US$/mg)
Table 41. Market Position of Manufacturers in Eptacog Alfa (rFVIIa), (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 42. Head Office and Eptacog Alfa (rFVIIa) Production Site of Key Manufacturer
Table 43. Eptacog Alfa (rFVIIa) Market: Company Product Type Footprint
Table 44. Eptacog Alfa (rFVIIa) Market: Company Product Application Footprint
Table 45. Eptacog Alfa (rFVIIa) New Market Entrants and Barriers to Market Entry
Table 46. Eptacog Alfa (rFVIIa) Mergers, Acquisition, Agreements, and Collaborations
Table 47. Global Eptacog Alfa (rFVIIa) Sales Quantity by Region (2018-2023) & (g)
Table 48. Global Eptacog Alfa (rFVIIa) Sales Quantity by Region (2024-2029) & (g)
Table 49. Global Eptacog Alfa (rFVIIa) Consumption Value by Region (2018-2023) & (USD Million)
Table 50. Global Eptacog Alfa (rFVIIa) Consumption Value by Region (2024-2029) & (USD Million)
Table 51. Global Eptacog Alfa (rFVIIa) Average Price by Region (2018-2023) & (US$/mg)
Table 52. Global Eptacog Alfa (rFVIIa) Average Price by Region (2024-2029) & (US$/mg)
Table 53. Global Eptacog Alfa (rFVIIa) Sales Quantity by Type (2018-2023) & (g)
Table 54. Global Eptacog Alfa (rFVIIa) Sales Quantity by Type (2024-2029) & (g)
Table 55. Global Eptacog Alfa (rFVIIa) Consumption Value by Type (2018-2023) & (USD Million)
Table 56. Global Eptacog Alfa (rFVIIa) Consumption Value by Type (2024-2029) & (USD Million)
Table 57. Global Eptacog Alfa (rFVIIa) Average Price by Type (2018-2023) & (US$/mg)
Table 58. Global Eptacog Alfa (rFVIIa) Average Price by Type (2024-2029) & (US$/mg)
Table 59. Global Eptacog Alfa (rFVIIa) Sales Quantity by Application (2018-2023) & (g)
Table 60. Global Eptacog Alfa (rFVIIa) Sales Quantity by Application (2024-2029) & (g)
Table 61. Global Eptacog Alfa (rFVIIa) Consumption Value by Application (2018-2023) & (USD Million)
Table 62. Global Eptacog Alfa (rFVIIa) Consumption Value by Application (2024-2029) & (USD Million)
Table 63. Global Eptacog Alfa (rFVIIa) Average Price by Application (2018-2023) & (US$/mg)
Table 64. Global Eptacog Alfa (rFVIIa) Average Price by Application (2024-2029) & (US$/mg)
Table 65. North America Eptacog Alfa (rFVIIa) Sales Quantity by Type (2018-2023) & (g)
Table 66. North America Eptacog Alfa (rFVIIa) Sales Quantity by Type (2024-2029) & (g)
Table 67. North America Eptacog Alfa (rFVIIa) Sales Quantity by Application (2018-2023) & (g)
Table 68. North America Eptacog Alfa (rFVIIa) Sales Quantity by Application (2024-2029) & (g)
Table 69. North America Eptacog Alfa (rFVIIa) Sales Quantity by Country (2018-2023) & (g)
Table 70. North America Eptacog Alfa (rFVIIa) Sales Quantity by Country (2024-2029) & (g)
Table 71. North America Eptacog Alfa (rFVIIa) Consumption Value by Country (2018-2023) & (USD Million)
Table 72. North America Eptacog Alfa (rFVIIa) Consumption Value by Country (2024-2029) & (USD Million)
Table 73. Europe Eptacog Alfa (rFVIIa) Sales Quantity by Type (2018-2023) & (g)
Table 74. Europe Eptacog Alfa (rFVIIa) Sales Quantity by Type (2024-2029) & (g)
Table 75. Europe Eptacog Alfa (rFVIIa) Sales Quantity by Application (2018-2023) & (g)
Table 76. Europe Eptacog Alfa (rFVIIa) Sales Quantity by Application (2024-2029) & (g)
Table 77. Europe Eptacog Alfa (rFVIIa) Sales Quantity by Country (2018-2023) & (g)
Table 78. Europe Eptacog Alfa (rFVIIa) Sales Quantity by Country (2024-2029) & (g)
Table 79. Europe Eptacog Alfa (rFVIIa) Consumption Value by Country (2018-2023) & (USD Million)
Table 80. Europe Eptacog Alfa (rFVIIa) Consumption Value by Country (2024-2029) & (USD Million)
Table 81. Asia-Pacific Eptacog Alfa (rFVIIa) Sales Quantity by Type (2018-2023) & (g)
Table 82. Asia-Pacific Eptacog Alfa (rFVIIa) Sales Quantity by Type (2024-2029) & (g)
Table 83. Asia-Pacific Eptacog Alfa (rFVIIa) Sales Quantity by Application (2018-2023) & (g)
Table 84. Asia-Pacific Eptacog Alfa (rFVIIa) Sales Quantity by Application (2024-2029) & (g)
Table 85. Asia-Pacific Eptacog Alfa (rFVIIa) Sales Quantity by Region (2018-2023) & (g)
Table 86. Asia-Pacific Eptacog Alfa (rFVIIa) Sales Quantity by Region (2024-2029) & (g)
Table 87. Asia-Pacific Eptacog Alfa (rFVIIa) Consumption Value by Region (2018-2023) & (USD Million)
Table 88. Asia-Pacific Eptacog Alfa (rFVIIa) Consumption Value by Region (2024-2029) & (USD Million)
Table 89. South America Eptacog Alfa (rFVIIa) Sales Quantity by Type (2018-2023) & (g)
Table 90. South America Eptacog Alfa (rFVIIa) Sales Quantity by Type (2024-2029) & (g)
Table 91. South America Eptacog Alfa (rFVIIa) Sales Quantity by Application (2018-2023) & (g)
Table 92. South America Eptacog Alfa (rFVIIa) Sales Quantity by Application (2024-2029) & (g)
Table 93. South America Eptacog Alfa (rFVIIa) Sales Quantity by Country (2018-2023) & (g)
Table 94. South America Eptacog Alfa (rFVIIa) Sales Quantity by Country (2024-2029) & (g)
Table 95. South America Eptacog Alfa (rFVIIa) Consumption Value by Country (2018-2023) & (USD Million)
Table 96. South America Eptacog Alfa (rFVIIa) Consumption Value by Country (2024-2029) & (USD Million)
Table 97. Middle East & Africa Eptacog Alfa (rFVIIa) Sales Quantity by Type (2018-2023) & (g)
Table 98. Middle East & Africa Eptacog Alfa (rFVIIa) Sales Quantity by Type (2024-2029) & (g)
Table 99. Middle East & Africa Eptacog Alfa (rFVIIa) Sales Quantity by Application (2018-2023) & (g)
Table 100. Middle East & Africa Eptacog Alfa (rFVIIa) Sales Quantity by Application (2024-2029) & (g)
Table 101. Middle East & Africa Eptacog Alfa (rFVIIa) Sales Quantity by Region (2018-2023) & (g)
Table 102. Middle East & Africa Eptacog Alfa (rFVIIa) Sales Quantity by Region (2024-2029) & (g)
Table 103. Middle East & Africa Eptacog Alfa (rFVIIa) Consumption Value by Region (2018-2023) & (USD Million)
Table 104. Middle East & Africa Eptacog Alfa (rFVIIa) Consumption Value by Region (2024-2029) & (USD Million)
Table 105. Eptacog Alfa (rFVIIa) Raw Material
Table 106. Key Manufacturers of Eptacog Alfa (rFVIIa) Raw Materials
Table 107. Eptacog Alfa (rFVIIa) Typical Distributors
Table 108. Eptacog Alfa (rFVIIa) Typical Customers
List of Figures
Figure 1. Eptacog Alfa (rFVIIa) Picture
Figure 2. Global Eptacog Alfa (rFVIIa) Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Eptacog Alfa (rFVIIa) Consumption Value Market Share by Type in 2022
Figure 4. Freeze-dried Preparation Examples
Figure 5. Freeze-dried Powder Examples
Figure 6. Global Eptacog Alfa (rFVIIa) Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 7. Global Eptacog Alfa (rFVIIa) Consumption Value Market Share by Application in 2022
Figure 8. Hemophilia Examples
Figure 9. Acquired Hemophilia Examples
Figure 10. Factor VII Deficiency Examples
Figure 11. Glanzmann Thrombasthenia (GT) Examples
Figure 12. Global Eptacog Alfa (rFVIIa) Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 13. Global Eptacog Alfa (rFVIIa) Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 14. Global Eptacog Alfa (rFVIIa) Sales Quantity (2018-2029) & (g)
Figure 15. Global Eptacog Alfa (rFVIIa) Average Price (2018-2029) & (US$/mg)
Figure 16. Global Eptacog Alfa (rFVIIa) Sales Quantity Market Share by Manufacturer in 2022
Figure 17. Global Eptacog Alfa (rFVIIa) Consumption Value Market Share by Manufacturer in 2022
Figure 18. Producer Shipments of Eptacog Alfa (rFVIIa) by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 19. Top 3 Eptacog Alfa (rFVIIa) Manufacturer (Consumption Value) Market Share in 2022
Figure 20. Top 6 Eptacog Alfa (rFVIIa) Manufacturer (Consumption Value) Market Share in 2022
Figure 21. Global Eptacog Alfa (rFVIIa) Sales Quantity Market Share by Region (2018-2029)
Figure 22. Global Eptacog Alfa (rFVIIa) Consumption Value Market Share by Region (2018-2029)
Figure 23. North America Eptacog Alfa (rFVIIa) Consumption Value (2018-2029) & (USD Million)
Figure 24. Europe Eptacog Alfa (rFVIIa) Consumption Value (2018-2029) & (USD Million)
Figure 25. Asia-Pacific Eptacog Alfa (rFVIIa) Consumption Value (2018-2029) & (USD Million)
Figure 26. South America Eptacog Alfa (rFVIIa) Consumption Value (2018-2029) & (USD Million)
Figure 27. Middle East & Africa Eptacog Alfa (rFVIIa) Consumption Value (2018-2029) & (USD Million)
Figure 28. Global Eptacog Alfa (rFVIIa) Sales Quantity Market Share by Type (2018-2029)
Figure 29. Global Eptacog Alfa (rFVIIa) Consumption Value Market Share by Type (2018-2029)
Figure 30. Global Eptacog Alfa (rFVIIa) Average Price by Type (2018-2029) & (US$/mg)
Figure 31. Global Eptacog Alfa (rFVIIa) Sales Quantity Market Share by Application (2018-2029)
Figure 32. Global Eptacog Alfa (rFVIIa) Consumption Value Market Share by Application (2018-2029)
Figure 33. Global Eptacog Alfa (rFVIIa) Average Price by Application (2018-2029) & (US$/mg)
Figure 34. North America Eptacog Alfa (rFVIIa) Sales Quantity Market Share by Type (2018-2029)
Figure 35. North America Eptacog Alfa (rFVIIa) Sales Quantity Market Share by Application (2018-2029)
Figure 36. North America Eptacog Alfa (rFVIIa) Sales Quantity Market Share by Country (2018-2029)
Figure 37. North America Eptacog Alfa (rFVIIa) Consumption Value Market Share by Country (2018-2029)
Figure 38. United States Eptacog Alfa (rFVIIa) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 39. Canada Eptacog Alfa (rFVIIa) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Mexico Eptacog Alfa (rFVIIa) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 41. Europe Eptacog Alfa (rFVIIa) Sales Quantity Market Share by Type (2018-2029)
Figure 42. Europe Eptacog Alfa (rFVIIa) Sales Quantity Market Share by Application (2018-2029)
Figure 43. Europe Eptacog Alfa (rFVIIa) Sales Quantity Market Share by Country (2018-2029)
Figure 44. Europe Eptacog Alfa (rFVIIa) Consumption Value Market Share by Country (2018-2029)
Figure 45. Germany Eptacog Alfa (rFVIIa) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. France Eptacog Alfa (rFVIIa) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. United Kingdom Eptacog Alfa (rFVIIa) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. Russia Eptacog Alfa (rFVIIa) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Italy Eptacog Alfa (rFVIIa) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. Asia-Pacific Eptacog Alfa (rFVIIa) Sales Quantity Market Share by Type (2018-2029)
Figure 51. Asia-Pacific Eptacog Alfa (rFVIIa) Sales Quantity Market Share by Application (2018-2029)
Figure 52. Asia-Pacific Eptacog Alfa (rFVIIa) Sales Quantity Market Share by Region (2018-2029)
Figure 53. Asia-Pacific Eptacog Alfa (rFVIIa) Consumption Value Market Share by Region (2018-2029)
Figure 54. China Eptacog Alfa (rFVIIa) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. Japan Eptacog Alfa (rFVIIa) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Korea Eptacog Alfa (rFVIIa) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. India Eptacog Alfa (rFVIIa) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. Southeast Asia Eptacog Alfa (rFVIIa) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. Australia Eptacog Alfa (rFVIIa) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. South America Eptacog Alfa (rFVIIa) Sales Quantity Market Share by Type (2018-2029)
Figure 61. South America Eptacog Alfa (rFVIIa) Sales Quantity Market Share by Application (2018-2029)
Figure 62. South America Eptacog Alfa (rFVIIa) Sales Quantity Market Share by Country (2018-2029)
Figure 63. South America Eptacog Alfa (rFVIIa) Consumption Value Market Share by Country (2018-2029)
Figure 64. Brazil Eptacog Alfa (rFVIIa) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 65. Argentina Eptacog Alfa (rFVIIa) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 66. Middle East & Africa Eptacog Alfa (rFVIIa) Sales Quantity Market Share by Type (2018-2029)
Figure 67. Middle East & Africa Eptacog Alfa (rFVIIa) Sales Quantity Market Share by Application (2018-2029)
Figure 68. Middle East & Africa Eptacog Alfa (rFVIIa) Sales Quantity Market Share by Region (2018-2029)
Figure 69. Middle East & Africa Eptacog Alfa (rFVIIa) Consumption Value Market Share by Region (2018-2029)
Figure 70. Turkey Eptacog Alfa (rFVIIa) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 71. Egypt Eptacog Alfa (rFVIIa) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Saudi Arabia Eptacog Alfa (rFVIIa) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. South Africa Eptacog Alfa (rFVIIa) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 74. Eptacog Alfa (rFVIIa) Market Drivers
Figure 75. Eptacog Alfa (rFVIIa) Market Restraints
Figure 76. Eptacog Alfa (rFVIIa) Market Trends
Figure 77. Porters Five Forces Analysis
Figure 78. Manufacturing Cost Structure Analysis of Eptacog Alfa (rFVIIa) in 2022
Figure 79. Manufacturing Process Analysis of Eptacog Alfa (rFVIIa)
Figure 80. Eptacog Alfa (rFVIIa) Industrial Chain
Figure 81. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 82. Direct Channel Pros & Cons
Figure 83. Indirect Channel Pros & Cons
Figure 84. Methodology
Figure 85. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
